Business Context and Reporting Period
This Form 8-K Current Report was filed by Praxis Precision Medicines, Inc. on May 21, 2022. The report discloses corporate governance changes effective May 23, 2022, specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the election of Jill DeSimone to the Board of Directors as a Class I director. The Board determined that Ms. DeSimone is independent under Nasdaq listing standards. Her term will serve until the 2024 Annual Meeting of Stockholders or until a successor is elected.
Guidance, Outlook, and Compensation
Ms. DeSimone will be compensated pursuant to the Company's Non-Employee Director Compensation Policy. Her compensation package includes:
- An initial stock option award.
- An annual cash retainer.
- An annual stock option award, subject to continued service.
Ms. DeSimone has entered into an indemnification agreement consistent with those of existing non-employee directors. There are no related person transactions requiring disclosure under Item 404(a) of Regulation S-K. The filing contains no financial guidance, risk factors, or unusual items.
Key Facts for Investors
- Board Composition: Jill DeSimone joins the Board as an independent Class I director effective May 23, 2022.
- Compensation Structure: New director receives cash retainers and stock options aligned with existing non-employee director policies.
- Independence: The Board has confirmed Ms. DeSimone's independence status per Nasdaq standards.
- Financial Data: No financial metrics or operational updates are included in this specific filing.